Beijing's Genecast Completes $149 Million E Round for Cancer Diagnostics

Genecast ( Beijing ) Technology completed a $149 million Series E financing to develop its second-generation sequencing technology and bioinformatics. Founded in 2014, Genecast has developed a circulating tumor DNA detection technology to provide individualized cancer diagnoses. The E Round was led by China Structural Reform Fund, and joined by Taikang Asset Management, CCB Private Equity Investment Management, Hillhouse Capital’s VC unit GL Ventures and China Renaissance. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.